You’re a pinch-hitter at an away game—the second in a double header—and you’re up to bat after the last pitch resulted in an eye-popping homerun. Six thousand are watching. Oh, and hundreds of millions of dollars are at stake.
That’s somethings similar the situation that confronted Seeger Weiss partner David Buchanan on the eve of the latest trial over the testosterone replacement therapy AndroGel, which ended last week with a $140 million verdict in punitive damages against Abbott Laboratories spin-off AbbVie.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
